Tesamorelin vs Sermorelin (and Ipamorelin, CJC-1295)
By DoseGauge Editorial · Updated 2026-06-13 · 6 min read
All four of these are growth-hormone-related peptides, and the cleanest way to tell them apart is by class and regulatory status. Tesamorelin and sermorelin are growth-hormone-releasing hormone (GHRH) analogues. Ipamorelin is a growth hormone secretagogue, specifically a ghrelin-receptor agonist (also called a GHRP). CJC-1295 is a long-acting GHRH analogue that is often paired with ipamorelin in a single blend. Of the four, only tesamorelin has an FDA-approved indication: it is sold as Egrifta for HIV-associated lipodystrophy. Sermorelin, ipamorelin, and CJC-1295 are not FDA-approved finished products for body composition or anti-aging. None of that is a recommendation. This page describes the differences and does not rate one peptide as best.
Class and mechanism
Growth hormone release from the pituitary is governed largely by two upstream signals: growth-hormone-releasing hormone (GHRH), which stimulates release, and ghrelin acting at its own receptor, which also drives release through a separate pathway. The four peptides on this page act on one of those two levers.
Tesamorelin and sermorelin are GHRH analogues. They mimic endogenous GHRH and bind the GHRH receptor on the pituitary, prompting the gland to release its own growth hormone in a pulse. Sermorelin is based on the first 29 amino acids of human GHRH. Tesamorelin is a stabilized GHRH analogue.
CJC-1295 is also a GHRH analogue, built on a modified GRF 1-29 sequence. The variant most often used in blends is CJC-1295 without DAC (modified GRF 1-29), which has a short plasma half-life of roughly 30 minutes; a separate variant with DAC binds albumin and persists for days. In both cases the mechanism is the GHRH lever.
Ipamorelin is different. It is a growth hormone secretagogue, a selective ghrelin-receptor agonist (a GHRP). Rather than mimicking GHRH, it acts at the ghrelin receptor to trigger growth hormone release through the complementary pathway. That is why ipamorelin is frequently paired with a GHRH analogue such as CJC-1295: the two push on different upstream levers.
Comparison table
| Peptide | Class | FDA-approved indication | Route and frequency | Notes |
|---|---|---|---|---|
| Tesamorelin | GHRH analogue | HIV-associated lipodystrophy (Egrifta) | Subcutaneous, once daily | Pivotal-trial-backed FDA approval for one indication. Egrifta SV: 1.4 mg/day; Egrifta WR: 1.28 mg/day. |
| Sermorelin | GHRH analogue | None for body composition | Subcutaneous, typically once daily at bedtime | Based on GHRH 1-29. Formerly marketed as Geref (discontinued 2008 for business reasons); now supplied via compounding. |
| Ipamorelin | Growth hormone secretagogue (ghrelin-receptor agonist / GHRP) | None; not approved for human use | Subcutaneous (research use) | Selective secretagogue. Often combined with a GHRH analogue. |
| CJC-1295 | Long-acting GHRH analogue | None; not approved for human use | Subcutaneous (research use) | Modified GRF 1-29. No-DAC and with-DAC variants differ greatly in duration. Often blended with ipamorelin. |
Approval status and what that means
Tesamorelin is the only one of the four with FDA approval. It is approved as Egrifta for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, an indication backed by pivotal clinical trials and described in the current prescribing information. That approval is narrow: it covers one population and one indication, not general body composition or anti-aging use. Use at other doses or for other purposes is off-label.
Sermorelin does not have a current FDA-approved finished product for body composition. It was formerly marketed as Geref, which was discontinued commercially in 2008 for business reasons unrelated to safety or efficacy, and it is now supplied through compounding pharmacies. Compounded use is not an FDA approval of a finished drug product.
Ipamorelin and CJC-1295 are research peptides and are not FDA-approved for human use. They are commonly sold together as a single blended vial. Describing them by class and mechanism, as above, is accurate; claiming an approved indication for either would not be.
The practical takeaway is that "growth hormone peptide" covers a spectrum from one drug with a specific FDA-approved use (tesamorelin) to compounds with no approved finished product for body composition (sermorelin, ipamorelin, CJC-1295).
How they are dosed and reconstituted
All four are subcutaneous peptides supplied as a lyophilized (freeze-dried) powder that you reconstitute with bacteriostatic water before drawing a dose. The arithmetic is the same idea in each case: your vial strength and water volume set the concentration, and your target dose sets the number of units to draw on a U-100 insulin syringe. The milligram and microgram scales differ between these compounds, so a unit count for one is not transferable to another. Run each one through its own calculator.
For the blended pair, use the CJC-1295 and ipamorelin calculator, which also shows how much of each peptide a single draw delivers. For background on the one peptide here with an FDA indication, see what tesamorelin is.
This page and the calculators perform math on the values you enter. They do not recommend any dose. Informational and educational only. Not medical advice. Consult a licensed clinician before using any peptide or hormone.
Frequently asked questions
Is tesamorelin better than sermorelin?
This page does not rate one as better. The factual differences: both are GHRH analogues, but only tesamorelin has an FDA-approved indication (Egrifta, for HIV-associated lipodystrophy), while sermorelin has no current FDA-approved finished product for body composition and is supplied via compounding. "Better" depends on context, indication, and an individual clinical picture, which is a conversation for a licensed clinician.
What is the difference between tesamorelin and ipamorelin?
They sit in different classes. Tesamorelin is a GHRH analogue that mimics GHRH at the pituitary GHRH receptor. Ipamorelin is a growth hormone secretagogue that acts at the ghrelin receptor, a separate pathway. Tesamorelin also has an FDA-approved indication (Egrifta), whereas ipamorelin is a research peptide that is not FDA-approved for human use.
Can you take tesamorelin and ipamorelin together?
A GHRH analogue and a secretagogue act on different upstream pathways, and such pairings (most commonly CJC-1295 with ipamorelin) are sometimes combined in research and clinical settings for that reason. Describing that a pairing exists is not a recommendation to use it. Whether any combination is appropriate is a decision for a licensed clinician, and ipamorelin is not FDA-approved for human use.
Which growth hormone peptide is FDA-approved?
Among the four compared here, only tesamorelin has an FDA-approved indication: it is sold as Egrifta for HIV-associated lipodystrophy. Sermorelin, ipamorelin, and CJC-1295 do not have a current FDA-approved finished product for body composition or anti-aging.
Informational and educational only. Not medical advice. DoseGauge computes from the values you enter and does not recommend a dose. Talk to a licensed clinician before using any peptide or GLP-1 medication.